. 2019 Nov 29;20:72. doi: 10.1186/s40360-019-0363-1

Table 2.

Results summary

Outcome measures		FEX vs. 1st gen AH				FEX vs. 2nd gen AH				FEX vs. PL
Outcome measures		Included studies	number	Heterogeneity (%)	P	Included studies	number	Heterogeneity (%)	P	Included studies	number	Heterogeneity (%)	P
Antihistamine effects	Inhibition rate of wheal					5	130	99	0.210	5	104	8	<0.001
Antihistamine effects	Inhibition rate of flare					4	100	100	0.840	5	176	96	< 0.001
Safety profiles	AE	10	522	0	0.031	22	5699	0	0.890	37	8591	0	0.987
	SE	10	522	0	0.046	27	6471	0	0.002	38	8700	0	0.120
	CFF	6	232	98	<0.001	3	118	89	0.280	6	232	85	0.170
	CRT	7	254	97	<0.001	4	140	76	0.220	6	206	89	0.280
	CTT	3	92	98	0.040	3	92	48	<0.001	3	92	95	0.960
	LARS	7	272	99	0.003	3	118	96	0.002	7	272	90	<0.001
	VAS of drowsiness	2	102	0	<0.001					3	116	97	0.070